A new Yale-led study published Thursday identified a new target for treating the most common form of cancer in children and ...
MedPage Today on MSN
CAR7 Gene Therapy Shows Promise in T-Cell ALL
The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how ...
Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...
Acute lymphoblastic leukemia (ALL) is known as a pediatric leukemia, with approximately half of cases occurring in children. ALL is the most common childhood malignancy, representing 75% to 80% of ...
Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...
Acute lymphoblastic leukemia (ALL) may be confused with different types of hematological conditions. Confusion of ALL diagnosis with acute myeloid leukemia (AML), hairy cell leukemia and malignant ...
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback